Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTTX NASDAQ:KDLY NASDAQ:PEAR NASDAQ:VSEE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTTXBetter Therapeutics$0.00$0.00▼$0.00$5K0.9715,895 shsN/AKDLYKindly MD$7.50-1.4%$12.90$0.65▼$34.77$45.17MN/A2.29 million shs214,285 shsPEARPear Therapeutics$0.00$0.03▼$6.74$4.17M0.457.75 million shs66.30 million shsVSEEVSee Health$1.32-3.6%$1.22$1.00▼$3.54N/AN/AN/A46,535 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTTXBetter Therapeutics0.00%0.00%0.00%-50.00%0.00%KDLYKindly MD-1.45%+3.88%-41.91%+90.84%+402.11%PEARPear Therapeutics0.00%0.00%0.00%0.00%0.00%VSEEVSee Health-3.65%+9.09%+7.32%+12.82%-55.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTTXBetter TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKDLYKindly MDN/AN/AN/AN/AN/AN/AN/AN/APEARPear TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVSEEVSee Health1.3494 of 5 stars2.04.00.00.01.10.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTTXBetter Therapeutics 0.00N/AN/AN/AKDLYKindly MD 0.00N/AN/AN/APEARPear Therapeutics 0.00N/AN/AN/AVSEEVSee Health 4.00Strong Buy$5.00278.79% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTTXBetter TherapeuticsN/AN/AN/AN/AN/AN/AKDLYKindly MD$2.47M18.28N/AN/AN/A∞PEARPear Therapeutics$12.69M0.00N/AN/A$0.22 per share0.00VSEEVSee HealthN/AN/AN/AN/A($3.40) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTTXBetter Therapeutics-$39.76MN/A0.00N/AN/AN/AN/AN/AN/AKDLYKindly MDN/A-$0.77N/A∞N/AN/AN/AN/AN/APEARPear Therapeutics-$75.49M-$0.22N/AN/AN/A-594.70%-217.85%-95.20%N/AVSEEVSee Health-$4.41MN/A0.00∞N/AN/AN/AN/A9/22/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTTXBetter TherapeuticsN/AN/AN/AN/AN/AKDLYKindly MDN/AN/AN/AN/AN/APEARPear TherapeuticsN/AN/AN/AN/AN/AVSEEVSee HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTTXBetter TherapeuticsN/AN/AN/AKDLYKindly MDN/A5.435.42PEARPear TherapeuticsN/A1.481.48VSEEVSee HealthN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTTXBetter Therapeutics34.00%KDLYKindly MDN/APEARPear Therapeutics71.17%VSEEVSee Health1.01%Insider OwnershipCompanyInsider OwnershipBTTXBetter Therapeutics51.40%KDLYKindly MD50.50%PEARPear Therapeutics30.70%VSEEVSee Health6.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTTXBetter Therapeutics4049.86 million24.23 millionOptionableKDLYKindly MDN/A6.02 million2.96 millionN/APEARPear Therapeutics300142.74 million98.92 millionNot OptionableVSEEVSee HealthN/A3.60 million3.37 millionN/APEAR, KDLY, VSEE, and BTTX HeadlinesRecent News About These CompaniesCORRECTING and REPLACING VSee New AI Doctor Notes Reduces Documentation Time 93% – Transforming Virtual Emergency Care for Tele911July 16, 2025 | businesswire.comVSee Health stock soars after launching AI doctor notes solutionJuly 14, 2025 | in.investing.comVSee Health Stock Jumps After Unveiling AI-Powered Doctor Notes ToolJuly 14, 2025 | msn.comVSee New AI Doctor Notes Reduces Documentation Time 93% – Transforming Virtual Emergency Care for Tele911July 14, 2025 | businesswire.comVSee Health ($VSEE): AI Telehealth Powerhouse Tapped for NIH Stroke Study as It Redefines the $787B Digital Healthcare MarketJune 26, 2025 | theglobeandmail.comVSee Health selected for NIH-funded stroke recovery telerehab trialJune 25, 2025 | investing.comVSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial - Business WireJune 24, 2025 | businesswire.comVSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical TrialJune 23, 2025 | businesswire.comVSee Health faces Nasdaq compliance issue over late filingsJune 1, 2025 | investing.comVSee Health faces Nasdaq delisting over late filingJune 1, 2025 | uk.investing.comVSee Health, Inc. Receives Nasdaq Notice on Delayed Form 10-Q FilingMay 30, 2025 | businesswire.comVSee Health launches telehealth initiative in the PhilippinesMay 17, 2025 | investing.comVSee Health Launches AI-Powered Telehealth to Reduce Maternal Deaths in Remote PhilippinesMay 16, 2025 | businesswire.comVSee Health, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K FilingMay 12, 2025 | businesswire.comVSee Health Inc. Faces Nasdaq Delisting Over Late FilingMay 10, 2025 | investing.comVSee Health unveils AI-driven telenursing platformApril 18, 2025 | uk.investing.comVSee Unveils Advanced Telenursing Robotics Solution Targeting 3-5% Reduction in Hospital Nursing CostsApril 16, 2025 | finance.yahoo.comVSee Health Highlights: AI-Powered Telehealth Redefining the $787 Billion Digital Healthcare Market Featured Image featured image Admin MessageApril 2, 2025 | markets.businessinsider.comVSee Health Highlights: AI-Powered Telehealth Redefining the $787 Billion Digital Healthcare MarketApril 2, 2025 | prnewswire.comVSee Health issues letter to shareholders updating progressMarch 7, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025View Why the American Eagle Stock Rally Isn't Just Speculation America Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?D-Wave Rises 12% in 1 Day, Beating Rivals: What Caused the Spike?By Nathan Reiff | July 22, 2025View D-Wave Rises 12% in 1 Day, Beating Rivals: What Caused the Spike?Why Now Could Be the Smartest Time to Buy Crypto StocksBy Nathan Reiff | July 10, 2025View Why Now Could Be the Smartest Time to Buy Crypto StocksPEAR, KDLY, VSEE, and BTTX Company DescriptionsBetter Therapeutics NASDAQ:BTTXBetter Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.Kindly MD NASDAQ:KDLY$7.50 -0.11 (-1.45%) As of 08/7/2025Kindly MD, Inc. provides healthcare services. Its services include medication management, behavioral healthcare and alternative treatments. The firm offers evaluation and management, including chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy. The company was founded by Timothy Pickett in December 2019 and is headquartered in Murray, UT.Pear Therapeutics NASDAQ:PEARPear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.VSee Health NASDAQ:VSEE$1.32 -0.05 (-3.28%) As of 08/8/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.VSee Health, Inc. is a no-code or low-code software as a service (SaaS) platform that enables clinicians and enterprises to create their telehealth workflows without programming. It engages in providing timely, quality healthcare to patients regardless of geographical barriers. The company is headquartered in Boca Raton, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
